All In Biotech

Drug Trial Radar · NCT05744921

A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

202

Planned (sponsor's estimate)

Start

Mar 7, 2023

Primary completion

Oct 10, 2028

Study completion Oct 10, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Feb 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of this study is to see how safe and effective the pozelimab + cemdisiran combination is for people with PNH in the long term. The pozelimab + cemdisiran combination may be referred to as "study drugs" in this section. This study is looking at several other research questions, including: * How effective is the pozelimab + cemdisiran combination? * What side effects may happen from taking the study drugs? * How much of each study drug is in the blood at different times? * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • PozelimabDrug

    Administered per the protocol

  • CemdisiranDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent serious adverse events (SAEs)Time frame: Up to week 108
  2. Severity of treatment-emergent SAEsTime frame: Up to week 108
  3. Incidence of treatment emergent adverse events of special interest (AESIs)Time frame: Up to week 108
  4. Severity of treatment emergent AESIsTime frame: Up to week 108
  5. Incidence of adverse events (AEs) leading to permanent treatment discontinuationTime frame: Up to week 108
  6. Severity of adverse events (AEs) leading to permanent treatment discontinuationTime frame: Up to week 108
  7. Percent change from baseline in lactate dehydrogenase (LDH)Time frame: Baseline to week 36

Locations

50 sites in 21 countries. Site status is shown where the registry gives one.

  • A Beneficencia Portuguesa de Sao Paulo, BP Mirante

    São Paulo, Brazil · Recruiting

  • Liga Paranaense de Combate Ao Cancer - Hospital Erasto Gaertner

    Curitiba, Jardim Santo Andre, Brazil · Recruiting

  • Toronto General Hospital

    Toronto, Ontario, Canada · Recruiting

  • Hospital Pablo Tobon Uribe

    Medellín, Antioquia, Colombia · Recruiting

  • Semmelweis University/Semmelweis Egyetem

    Budapest, Hungary · Recruiting

  • Postgraduate Institute of Medical Education & Research

    Chandigarh, India · Recruiting

  • Bhagwan Mahaveer Cancer Hospital and Research Centre (BMCHRC)

    Jaipur, India · Recruiting

  • Amrita Institute of Medical Sciences (AIMS) and Research Centre Aims

    Kochi, Kerala, India · Recruiting

  • K J Somaiya Super Specialty Hospital & Research Centre

    Mumbai, Maharashtra, India · Recruiting

  • Rajiv Gandhi Cancer Institute & Research Center (RGCIRC) - Rohini Campus

    New Delhi, National Capital Territory of Delhi, India · Recruiting

  • SC Hematology, AOU Città della Salute e della Scienza di Torino

    Torino, Italy · Recruiting

  • Aou Careggi

    Florence, Firenze, Italy · Recruiting

  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital

    Nagoya, Aichi-ken, Japan · Withdrawn

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, Japan · Recruiting

  • Jordan University Hospital (JUH)

    Amman, Jordan · Recruiting

  • Hospital Tg Ampuan Afzan

    Kuantan, Pahang, Malaysia · Recruiting

  • Hospital Queen Elizabeth

    Kota Kinabalu, Sabah, Malaysia · Recruiting

  • Hospital Ampang

    Ampang, Selangor, Malaysia · Recruiting

  • Servicio de Hematologia del Hospital Universitario de la UANL

    Monterrey, Nuevo León, Mexico · Recruiting

  • Clinica San Felipe

    Lima, Peru · Recruiting

  • St Lukes Medical Center

    Quezon City, National Capital Region, Philippines · Recruiting

  • Szpital Uniwersytecki Nr2 Bydgoszcz

    Bydgoszcz, Poland · Completed

  • In-Vivo Sp. z o.o.

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting

  • University Clinical Center Medical University of Gdansk

    Gdansk, Pomeranian Voivodeship, Poland · Recruiting

  • Prof Dr Ion Chiricuta Cancer Institute

    Cluj-Napoca, Cluj, Romania · Recruiting

  • National University Hospital

    Singapore, Singapore · Recruiting

  • Pusan National University Hospital

    Busan, South Korea · Recruiting

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea · Recruiting

  • Ewha Womans University Mokdong Hospital

    Seoul, South Korea · Recruiting

  • St. Vincent Hospital

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Ajou University Medical Center

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Gachon University Gil Medical Center

    Incheon, Namdong-Gu, South Korea · Recruiting

  • Hospital Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Universitario Basurto

    Bilbao, Vizcaya, Spain · Recruiting

  • Changhua Christian Hospital

    Changhua, Taiwan · Recruiting

  • Hualien Tzu Chi Hospital

    Hualien City, Taiwan · Recruiting

  • Taichung Veterans General Hospital (VGHTC)

    Taichung, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.